Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Myxopapillary ependymoma (MEPN) describes a slow growing ependymoma located almost exclusively in the conus medullaris-cauda equina-filum terminale region of the spinal cord, presenting in all age groups, and manifesting with variable symptoms such as neck pain, vomiting and unsteady gait and metastasis. It has a more aggressive disease course and is seen in the pediatric population.
Biomarker and diagnostic research for myxopapillary ependymoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for myxopapillary ependymoma.
138 publications have been identified in PubMed for myxopapillary ependymoma. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (27%), and Basic Science / Preclinical (22%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 35 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:34 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
31 |
27% |
Laboratory research | 26 | 22% |
Disease patterns and progression | 9 | 8% |
Testing and diagnosis research | 8 | 7% |
Clinical study results | 5 | 4% |
New treatment approaches | 2 | 2% |
Cooper E (2026). [PMID: 41634415](https://pubmed.ncbi.nlm.nih.gov/41634415/). *Nat Genet*. [Basic Science / Preclinical]
Shepherd L (2026). [PMID: 41518103](https://pubmed.ncbi.nlm.nih.gov/41518103/). *Pediatr Blood Cancer*. [Review / Meta-Analysis]
Kumaria A (2026). [PMID: 40794235](https://pubmed.ncbi.nlm.nih.gov/40794235/). *Brain Tumor Pathol*. [Review / Meta-Analysis]
Ghasemi DR (2026). [PMID: 41619789](https://pubmed.ncbi.nlm.nih.gov/41619789/). *Neuro Oncol*. [Review / Meta-Analysis]
Jeong D (2026). [PMID: 41813893](https://pubmed.ncbi.nlm.nih.gov/41813893/). *Nature*. [Basic Science / Preclinical]
Karataş D (2026). [PMID: 41205865](https://pubmed.ncbi.nlm.nih.gov/41205865/). *World Neurosurg*. [Case Report / Case Series]
Kardian AS (2026). [PMID: 41882368](https://pubmed.ncbi.nlm.nih.gov/41882368/). *Nature*. [Diagnostic / Biomarker]
Natarajan SK (2026). [PMID: 41639460](https://pubmed.ncbi.nlm.nih.gov/41639460/). *Nature*. [Basic Science / Preclinical]
Chen YC (2026). [PMID: 41982316](https://pubmed.ncbi.nlm.nih.gov/41982316/). *Neurosurg Pract*. [Diagnostic / Biomarker]
Arora S (2026). [PMID: 41159380](https://pubmed.ncbi.nlm.nih.gov/41159380/). *Neuro Oncol*. [Basic Science / Preclinical]